stroke - cerebral infarction - cerebral hemorrhage - dementia - mild cognitive impairment
acidente vascular cerebral - infarto cerebral - hemorragia cerebral - demência - comprometimento
cognitivo leve
Stroke survivors are at risk for (i) new vascular events such as recurrent stroke[1], myocardial infarction[2] or vascular death[3]; (ii) complications of treatments[4]; and (iii) delayed neurological complications, such as epileptic seizures[5],[6], cognitive impairment[7],[8], depression[9], and pain[10]. Cognitive impairment is one of the major causes of dependency after stroke[7],[8].
It is quite frequent that cognitive impairment, or even dementia, was already present
before the stroke[7],[8]. Stroke and cognitive impairment are both common, occur in the same age category,
and share similar risk factors[11]. Moreover, stroke lesions can lead to cognitive impairment, alone or in association
with Alzheimer pathology[11]. Most studies on the relationship between stroke and cognitive impairment have focused
on cognitive impairment occurring after stroke, or on patients with cognitive impairment
who have “apparently silent” brain lesions of vascular origin. However, although one
patient in six admitted for a stroke was already demented before the stroke[7],[12],[13],[14], and probably many more were cognitively impaired, little is known about the characteristics
of stroke occurring in patients with pre-existing cognitive decline, and about the
optimal management of stroke in these patients.
The objectives of this review were to determine how pre-existing cognitive impairment
in stroke patients can be detected, what their mechanisms are, and what their possible
influence on outcome and management are.
HOW TO DETECT PRE-EXISTING COGNITIVE IMPAIRMENT IN PATIENTS ADMITTED FOR STROKE?
As stroke lesions may induce neuropsychological deficits, it may be difficult to determine
whether or not the patient was demented before the stroke by an assessment of the
patient in the stroke unit: cognitive deficits detected after stroke onset may be
due to brain lesions related to the stroke, and were not present before the stroke[8]. Therefore, another strategy is needed. The global clinical impression based on
the clinical judgement of the physician after an interview with relatives or with
the general practitioner provides some information[15], but the reliability between and within physicians is poor. A systematic approach
with the Informant Questionnaire of Cognitive Decline in the Elderly (IQCODE)[16]provides more reliable and reproducible results. In the original version, this questionnaire
consisted of 26 questions regarding changes experienced by the patient over the last
10 years in various aspects of daily behaviour that require memory and other intellectual
abilities[16]. A close relative is interviewed and the participation of the patient is not required.
The IQCODE can, therefore, be used when the neuropsychological evaluation is possibly
influenced by stroke, or is not feasible because of coma or severe aphasia. A short
version of IQCODE is now available, with the 16 most relevant questions of the old
version[17], and has been validated in several languages.
Patients can be classified as previously demented when they have an IQCODE score of
104 or more (long version)[16] or 64 or more (short version)[17], and cognitively normal when they have an IQCODE score of 78 (long version)[16] or 64 (short version)[17]. The results at the IQCODE have an excellent correlation with those of the Mini-Mental
State Examination (MMSE) when tested in the community[18]. The limitations of the IQCODE are the need for a reliable informant who meets with
the patient at least once a week, and it to be used within 48 hours after admission
to prevent any influence on the relative by the current status of the patient[18]. These limitations explain why the IQCODE cannot be used in approximately 20% of
patients[12]. Another limitation is that the IQCODE is time-consuming.
How frequent is pre-existing cognitive impairment in stroke?
Pre-existing dementia, defined as an IQCODE score of 104 (long version) or 64 (short
version) or higher, has been reported with a frequency of 14.4% (95%CI 12.0% to 16.8%)
in hospital-based studies and 9.2% (95%CI 6.9% to 11.3%) in population-based studies[7]. The frequency of pre-stroke cognitive impairment with no dementia (CIND) is more
difficult to evaluate routinely, but seems to be much higher[19],[20].
Mechanisms of pre-existing cognitive impairment
Pre-existing cognitive impairment is due to the presence of brain lesions before stroke,
that can be of vascular, or degenerative origin, or both[21].
Various types of pre-existing brain lesions of vascular origin are frequently found
in patients with pre-existing dementia, but they have not been systematically evaluated
in large series of patients with pre-stroke CIND. These pre-existing brain lesions
consist of:
1) Previous strokes of any severity or type, found to be associated with pre-existing dementia in a pooled
analysis of six studies[7]: OR 2.2 (95%CI 1.6 to 3.0).
2) Silent infarcts are infarcts identified on the baseline computed tomographic (CT) or magnetic resonance
imaging (MRI) scan performed on admission, in the absence of any clinical history
of stroke or transient ischaemic attack that could be explained by the lesion on admission.
They are present in approximately 20% of patients admitted for acute stroke who underwent
a CT scan[22], and more in those who underwent a MRI scan. In the two studies of consecutive patients
with stroke, where the presence of silent infarcts was evaluated, silent infarcts
were present in 21 of 72 (29.2%) patients with pre-existing dementia and 98 of 334
(29.4%) without, suggesting no statistical relationship, with a large area of uncertainty
(odds ratio [OR] 1.00; 95%CI 0.4 to 2.4[7].
3) White matter changes are more frequent in patients who have pre-existing cognitive impairment (54 of 100
in patients with dementia vs. 187 of 672 in patients without, OR: 2.8; 95%CI: 1.4-5.6)[7]. Depending on the age of subjects, and imaging technique used, they can also be
found on CT or MRI scans of normal subjects[23]. However, at the community level, those who have white matter changes have a 1.9
fold increased risk (95%CI 1.3-2.8) of becoming demented[23]. In patients with mild cognitive impairment, patients with white matter changes
are more likely to decline[24] or become demented[25], with a dose effect relationship. These abnormalities are more frequent in subjects
with vascular risk factors, especially arterial hypertension, and previous strokes,
especially in association with small-vessel disease, such as lacunar infarcts and
deep spontaneous intracerebral haemorrhages. In stroke patients, these are independently
associated with an increased risk of post stroke dementia, recurrent stroke and myocardial
infarction[23].
4) Brain microbleeds have not specifically been studied in the context of pre-existing dementia. However,
they are more frequent in patients with recurrent strokes, intra-cerebral haemorrhages,
and dementia, but a causal relationship is not certain[26]. They may be just a marker of the underlying pathology that can be the cause of
dementia, especially in patients with lobar haemorrhages[21].
5) Brain atrophy present before stroke is frequent in patients with pre-existing dementia.
Medial temporal lobe atrophy is significantly more frequent in patients with pre-stroke
dementia (OR 7.7; 95%CI 4.3 to 13.8). Atrophy is usually considered as a marker of
Alzheimer’s disease[27], although it has been also reported as the consequence of pure vascular lesions[28]. There is actual evidence that global brain atrophy[29],[30] and medial temporal lobe atrophy can also be the consequence of pure vascular disorders[28].
Influence of pre-existing cognitive impairment on stroke outcome
Patients who have pre-existing cognitive impairment or dementia, have an overall worse
outcome compared to patients who were cognitively normal before stroke. They are more
likely, at the acute stage, to develop seizures[5], and delirium, especially in cases of co-existent infection or metabolic disorder[31], or to die[32]. After three years, they are more likely to die[32], or to develop depressive symptoms[33]. Patients with CIND are more likely to be institutionalised after a stroke[34].
Acute stroke management in patients with pre-existing cognitive impairment
Stroke unit care
Although stroke unit care is highly recommended for all stroke patients[35] without exception, patients with pre-existing cognitive impairment tend to be less
frequently admitted to stroke unit[36]. Pre-existing cognitive functioning was not considered in stroke unit trials, and
some of them even excluded patients with clearly identified pre-existing dementia.
There is no rationale to exclude these patients from stroke unit care, provided they
are not considered at a stage of purely palliative care.
Intravenous recombinant tissue plasminogen activator (rt-PA)
The license of intravenous recombinant tissue plasminogen activator (rt-PA) in the
European Union is restricted to patients aged 80 years or less in many countries,
but most centres do not follow this rule anymore[37]. According to the results from the 3rd International Stroke Trial[38] and the updated meta-analysis[39] that proved the efficacy of rt-PA in patients aged 80 years or more, the use of
rt-PA for elderly patients in clinical practice has increased. Therefore, more ischaemic
stroke patients with cognitive impairment are eligible for thrombolysis[40]. However, the safety and the efficacy of rt-PA for these patients are controversial.
These patients often have underlying brain pathology, such as leukoaraiosis, brain
microbleeds, multiple micro-infarcts as the consequence of cerebral amyloid angiopathy[41] or lipohyalinosis[42]. Leukoaraiosis has been reported as a risk for haemorrhagic transformation after
rt-PA[43]. Cerebral microbleeds[44] and small-vessel disease[45] are also markers of increased risks for haemorrhagic transformation. However other
studies have shown that this effect is modest and should not prevent the administration
of rt-PA[46]. Theoretically, patients with pre-stroke cognitive impairment may have a higher
sensitivity to the toxic effect of rt-PA and a lower capacity to recover from brain
injury[47]. Despite these theoretical reasons for the reduced efficacy of rt-PA and worse safety
profiles, no study has found an increased rate of haemorrhagic transformation after
intravenous rt-PA in patients with pre-stroke cognitive impairment[19],[20],[48],[49],[50].
Other acute stroke treatments
Other treatments validated at the acute stage of stroke, such as mechanical thrombectomy
and aspirin, have not been evaluated in patients with pre-stroke cognitive impairment.
Decompressive surgery is not really a matter of interest here because it is performed
in patients who are usually too young to be severely cognitively impaired before stroke.
Secondary stroke prevention in patients with pre-existing cognitive impairment
Management of vascular risk factors
At the chronic phase of stroke, arterial hypertension should be treated as a common
risk factor for recurrence of stroke, myocardial infarction and cognitive impairment.
Regarding stroke prevention, the lower blood pressure the better[51]. The positive effect of antihypertensive therapy on cognitive function has been
reported in several studies in primary prevention trials and in a secondary prevention
trial.
The benefit of diabetes medication on the prevention for cognitive decline is still
debated and there is no specific data on patients who have a stroke.
Systematic reviews found no deleterious effect of statins on the risks of intracerebral
haemorrhage in the primary and secondary prevention for vascular disease[52].
Aspirin
No study has evaluated the safety and efficacy of aspirin to prevent recurrence of
ischaemic stroke in patients with cognitive impairment. We need additional investigation
to test the safety of aspirin in secondary prevention of stroke among post stroke
cognitively impaired patients.
Oral anticoagulant
Anticoagulation is an established treatment in patients with atrial fibrillation for
the primary and secondary prevention of ischaemic stroke. It is reported that atrial
fibrillation patients with cognitive impairment are sometimes not treated with anticoagulation
although there is no clear contraindication[53]. A subgroup analysis of 2,510 patients with atrial fibrillation enrolled in the
ACTIVE-W showed that a low score on the MMSE was related to a short time-in-therapeutic-range
and caused more vascular events and bleeding[54]. Yet the rate of vascular event and bleeding were no longer different after adjustment
of time-in-therapeutic-range. On the contrary, another study revealed that mild to
moderate cognitive impairment did not require more time to achieve therapeutic anticoagulation,
or decreased anticoagulation stability, or extra intensive clinic management versus
patients with normal cognition[54]. This could depend on the environmental controls of the patients.
The equivalent efficacy for preventing ischaemic stroke and the lower risk for cerebral
haemorrhage with new oral anticoagulants are clear advantages in patients with cognitive
impairment, but they have not specifically been evaluated.
Carotid endarterectomy
Carotid endarterectomy (CEA) is recommended for selected patients with symptomatic
and asymptomatic carotid stenosis for the prevention of first and recurrent stroke[35]. The impact of CEA on the preoperative cognitive function remains debatable, and
no study has evaluated the risk:benefit ratio of CEA between cognitive change, functional
outcome and incidence of future stroke. Therefore, performing CEA for the purpose
of treating cognitive impairment is not recommended today; however, there is no reason
not to perform CEA when indicated because of preoperative cognitive dysfunction. In
future CEA trials, evaluation of the influence of preoperative cognitive function
on the outcome and postoperative cognitive function should be included as an outcome
measure.
In conclusion, patients with cognitive impairment who develop a stroke have worse
outcomes, both at the acute stage and during the follow up, with more dependency and
increased mortality. There is no reason not to treat these patients with the best
therapeutic strategy at the acute stage (stroke unit care in all patients, thrombolysis
and/or thrombectomy in eligible ischaemic stroke patients, aspirin in patients not
eligible for recanalization procedures or after 24 hours), and for secondary prevention
(optimal management of risk factors in all, antithrombotic in ischaemic stroke patients
– oral anticoagulant in cardiopathies, aspirin, and carotid surgery when appropriate.
Although the safety profile of different therapeutic strategies is not as good as
that of cognitively normal patients, the risk:benefit ratio is in favour of treating
these patients like others in most cases.
